Faron Pharmaceuticals Oy (FARN) - Total Liabilities
Based on the latest financial reports, Faron Pharmaceuticals Oy (FARN) has total liabilities worth GBX32.45 Million GBX (≈ $3.95K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Faron Pharmaceuticals Oy long-term investment allocation to see how much of total assets are deployed in long-term investments.
Faron Pharmaceuticals Oy - Total Liabilities Trend (2012–2024)
This chart illustrates how Faron Pharmaceuticals Oy's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Faron Pharmaceuticals Oy asset portfolio.
Faron Pharmaceuticals Oy Competitors by Total Liabilities
The table below lists competitors of Faron Pharmaceuticals Oy ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Redan S.A.
WAR:RDN
|
Poland | zł34.61 Million |
|
Lendinvest PLC
LSE:LINV
|
UK | GBX766.10 Million |
|
Reliance Industries Limited
IL:RIGD
|
UK | $10.92 Trillion |
|
Churchill China plc
LSE:CHH
|
UK | GBX15.76 Million |
|
Ariana Resources plc
LSE:AAU
|
UK | GBX2.34 Million |
|
Craven House Capital PLC
LSE:CRV
|
UK | $1.93 Million |
|
STMicroelectronics NV
LSE:0INB
|
UK | €7.83 Billion |
|
Aequus Pharmaceuticals Inc
V:AQS
|
Canada | CA$7.09 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Faron Pharmaceuticals Oy's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Faron Pharmaceuticals Oy balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Faron Pharmaceuticals Oy's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Faron Pharmaceuticals Oy (2012–2024)
The table below shows the annual total liabilities of Faron Pharmaceuticals Oy from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX22.28 Million ≈ $2.71K |
-12.21% |
| 2023-12-31 | GBX25.38 Million ≈ $3.09K |
+11.58% |
| 2022-12-31 | GBX22.75 Million ≈ $2.77K |
+121.62% |
| 2021-12-31 | GBX10.26 Million ≈ $1.25K |
+0.47% |
| 2020-12-31 | GBX10.22 Million ≈ $1.24K |
+18.80% |
| 2019-12-31 | GBX8.60 Million ≈ $1.05K |
+12.66% |
| 2018-12-31 | GBX7.63 Million ≈ $928.72 |
-24.75% |
| 2017-12-31 | GBX10.14 Million ≈ $1.23K |
+58.40% |
| 2016-12-31 | GBX6.40 Million ≈ $779.18 |
+75.79% |
| 2015-12-31 | GBX3.64 Million ≈ $443.25 |
+8.65% |
| 2014-12-31 | GBX3.35 Million ≈ $407.96 |
+5.24% |
| 2013-12-31 | GBX3.19 Million ≈ $387.64 |
+14.89% |
| 2012-12-31 | GBX2.77 Million ≈ $337.39 |
-- |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more